Financials

v3.10.0.1
Consolidated Balance Sheets - USD ($)
Sep. 30, 2017
Sep. 30, 2016
Current Assets:    
Cash $ 1,348 $ 851
Accounts receivable 41,383
Prepaid expenses
Total current assets 1,348 42,234
Non-current Assets    
Intellectual Property 5,078,060 5,497,134
Website development cost, net 4,250 5,312
Other Assets 46,560 20,000
Patent costs, net 98,987 111,361
Total non-current assets 5,227,857 5,633,807
Total Assets 5,229,205 5,676,041
Current Liabilities:    
Accounts payable 1,106,607 536,630
Accrued expenses 542,340 518,932
Accrued payroll and benefits 277,175 256,480
Convertible notes payable 250,807
Convertible notes payable to related party 400,000 429,280
Derivative liability 1,926,800 123,239
Total current liabilities 4,252,921 2,115,369
Total Liabilities 4,252,921 2,115,369
Commitments and Contingencies  
Stockholders' Equity    
Common Stock $0.00001 par value, 450,000,000 shares authorized; 303,927,098 and 219,254,543 shares outstanding as of September 30, 2017 and September 30, 2016, respectively 3,040 2,193
Additional paid-in capital 32,132,294 25,131,601
Accumulated deficit (31,159,051) (21,573,123)
Total Stockholders' Equity 976,283 3,560,671
Total Liabilities and Stockholders' Equity 5,229,205 5,676,041
Series B Preferred Stock [Member]    
Stockholders' Equity    
Preferred stock value

Source

v3.10.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Income Statement [Abstract]    
Revenue $ 255,951 $ 118,040
Cost of revenue 27,672 52,522
Gross profit 228,279 65,518
Operating expenses:    
Selling, general and administrative 2,589,795 1,230,992
Amortization Fees
Research and development
Research and development - license acquired 10,080,000
Professional fees 5,962,332 313,275
Merger costs
Total operating expenses 8,552,127 11,624,267
Loss from operations (8,323,848) (11,558,749)
Other income    
Interest income 4,034
Gain on other comprehensive income 98,897
Total other expense 102,931
Other expense    
Interest expense 695,741 (114,253)
Other finance expense 595,733
Loss on other comprehensive expense 100,000 (126,344)
Loss on change in fair value of derivative (26,463) 40,302
Total other expense 1,365,011 (200,295)
Net Gain/ (Loss) $ (9,585,928) $ (11,759,045)
Loss per Share:    
Basic and diluted net loss per common share outstanding $ (0.05) $ (0.08)
Basic and diluted weighted average number of common shares outstanding 200,170,287 146,223,688
Comprehensive loss:    
Net loss $ (9,585,928) $ (11,759,045)
Unrealized loss on available for sale securities
Comprehensive gain/(loss) $ (9,585,928) $ (11,759,045)

Source

v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Cash Flows from Operating Activities:    
Net loss $ (9,585,928) $ (11,759,045)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 447,637 340,039
Amortization of debt discounts 18,865
Amortization of patent and web design costs
Research and development - license acquired 10,080,000
Stock-based compensation expenses 7,001,440 77,522
Loss on change in fair value of derivatives 1,803,561 86,042
Changes in operating assets and liabilities:    
Accounts receivable 41,383 64,251
Prepaid Expenses 42
Accounts payable 569,975 174,390
Accrued payroll and benefits
Due to related party 20,695
Accrued liabilities 23,408 234,890
Net cash used in operating activities 322,171 (683,004)
Cash Flows from Investing Activities:    
Cash acquired with acquisition of Theranostics Health, Inc. assets 37,519
Licensing costs (15,127) (16,856)
Other Assets (26,560) (20,000)
Website development costs (21,250)
Net cash provided by (used in) investing activities (41,687) (20,587)
Cash Flows from Financing Activities:    
Proceeds from sale of common stock, net 100 310,000
Proceeds from convertible notes payable (280,087) 250,807
Proceeds from convertible notes payable, related party 100,000
Net cash provided by financing activities (279,987) 660,807
Net increase in cash 497 (42,784)
Cash at beginning of period 851 43,635
Cash at end of period 1,348 851
Supplemental disclosure of noncash investing and financing activities:    
Shares issued in settlement of related party debt 428,575
Reclass derivative liability to equity upon note payment 52,389
Common stock issued to acquire net assets of Theranostics Health, Inc. 3,150,000
Common stock issued to acquire net assets of Amarantus Diagnostics, Inc. $ 10,080,000

Source